This Article Full Text Full Text (PDF) Supplemental Table All Versions of this Article: 145/5/2214    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wellen, K. E. Articles by Hotamisligil, G. S. Search for Related Content PubMed PubMed Citation Articles by Wellen, K. E. Articles by Hotamisligil, G. S.

Interaction of Tumor Necrosis Factor-- and Thiazolidinedione-Regulated Pathways in Obesity

Division of Biological Sciences and Department of Genetics and Complex Diseases (K.E.W., K.T.U., S.W., G.S.H.), Harvard School of Public Health, Boston, Massachusetts 02115; and Millennium Pharmaceuticals (Q.Y., H.C.), Cambridge, Massachusetts 02142

Address all correspondence and requests for reprints to: Gökhan S. Hotamisligil, M.D., Ph.D., Harvard School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02115. E-mail: ghotamis{at}hsph.harvard.edu.

Thiazolidinediones (TZDs) are potent insulin-sensitizing compounds and high-affinity ligands for the transcription factor peroxisomal proliferator-activated receptor . The mechanism through which TZDs improve insulin sensitivity, however, is not clear. In this study, we asked whether the ability of TZD to suppress and antagonize TNF is an underlying mechanism for its molecular and physiological effects, using obese (ob/ob) mice lacking TNF function. We found that the lipid-lowering effects of TZD are completely independent of TNF suppression, and the insulin-sensitizing effects of TZD are partially independent. TZD treatment improved insulin sensitivity in ob/ob mice both with and without functional TNF, albeit with different absolute potency. To characterize the potential interdependency of TZD- and TNF-regulated pathways at the molecular level, we also performed four-way transcriptional profiling of white adipose tissue of TZD- and vehicle-treated ob/ob mice, with and without TNF function. The majority of metabolic genes identified were regulated independent of the presence of TNF, whereas most effects on inflammatory mediators were dependent on TNF. This study demonstrates that the insulin-sensitizing action of TZD occurs partially through TNF-independent mechanisms, although a subset of the molecular effects of TZD treatment in adipose tissue depends on TNF.

This article has been cited by other articles:

				M. Kolak, H. Yki-Jarvinen, K. Kannisto, M. Tiikkainen, A. Hamsten, P. Eriksson, and R. M. Fisher Effects of Chronic Rosiglitazone Therapy on Gene Expression in Human Adipose Tissue in Vivo in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 720 - 724. [Abstract] [Full Text] [PDF]

				N. Kubota, Y. Terauchi, T. Kubota, H. Kumagai, S. Itoh, H. Satoh, W. Yano, H. Ogata, K. Tokuyama, I. Takamoto, et al. Pioglitazone Ameliorates Insulin Resistance and Diabetes by Both Adiponectin-dependent and -independent Pathways J. Biol. Chem., March 31, 2006; 281(13): 8748 - 8755. [Abstract] [Full Text] [PDF]

				A. R. Nawrocki, M. W. Rajala, E. Tomas, U. B. Pajvani, A. K. Saha, M. E. Trumbauer, Z. Pang, A. S. Chen, N. B. Ruderman, H. Chen, et al. Mice Lacking Adiponectin Show Decreased Hepatic Insulin Sensitivity and Reduced Responsiveness to Peroxisome Proliferator-activated Receptor {gamma} Agonists J. Biol. Chem., February 3, 2006; 281(5): 2654 - 2660. [Abstract] [Full Text] [PDF]

				C. J. Nicol, M. Yoon, J. M. Ward, M. Yamashita, K. Fukamachi, J. M. Peters, and F. J. Gonzalez PPAR{gamma} influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis Carcinogenesis, September 1, 2004; 25(9): 1747 - 1755. [Abstract] [Full Text] [PDF]